Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Caplin Point Laboratories
Mid Cap•3,406 Employees•IPO 1994
Current Price
₹1684.10
13.5 (0.81%)Updated
Today's Range
₹1665.60
₹1690.00
₹1684.10
52 Week Range
52W Low₹1599.00
52W High₹2395.00
₹1684.10
Downside5.32%
Upside42.21%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹13,093.4 Cr
Market Cap
Total market value of companyP/E Ratio
21.34
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.73
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹80.49
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
9.88%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
25.80%
ROCE
Return on Capital Employed. >15% is goodNet Margin
29.37%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
19.95%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
17.55%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
11.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
23.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹375.01
Book Value
Net asset value per shareDividend Yield
0.49%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
70.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
6 points- •Caplin Point demonstrates robust financial health with an impressive ROE of 22.70%, ROCE of 25.80%, and OPM of 33.80%, showcasing efficient capital utilization and strong profitability.
- •The company exhibits consistent growth, with quarterly sales increasing by 11.20% and net profit by 23.30%, indicating strong market demand and effective operational execution.
Weaknesses
4 points- •The stock has shown significant volatility, with a 52-week high of ₹2641 and a low of ₹1551, indicating considerable market risk and potential price fluctuations for investors.
- •Caplin Point's P/E ratio of 27.20, while close to the sector average, is higher than some established peers like Dr Reddy's (18.07%) and Cipla (23.66%), potentially limiting valuation upside.
Opportunities
4 points- •The expanding global pharmaceuticals market, driven by increasing healthcare access and demand, presents significant avenues for Caplin Point to grow its international presence.
- •Leveraging its strong financial position, the company has an opportunity to pursue strategic acquisitions to expand its product portfolio or enter new therapeutic segments.
Threats
4 points- •The highly competitive pharmaceutical landscape, with numerous domestic and international players, poses a constant threat to market share and pricing power for Caplin Point.
- •Stringent and evolving regulatory requirements in key markets could lead to increased compliance costs, delays in product approvals, or potential operational disruptions.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1743.00 | +₹58.90 | +3.50% |
| R3 | ₹1718.60 | +₹34.50 | +2.05% |
| R2 | ₹1704.30 | +₹20.20 | +1.20% |
| R1 | ₹1694.20 | +₹10.10 | +0.60% |
| PIVOT | ₹1679.90 | -4.20 | -0.25% |
| CURRENT | ₹1684.10 | - | - |
| S1 | ₹1621.00 | -₹63.10 | -3.75% |
| S2 | ₹1645.40 | -₹38.70 | -2.30% |
| S3 | ₹1655.50 | -₹28.60 | -1.70% |
| S4 | ₹1669.80 | -₹14.30 | -0.85% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+25.3% vs avg
0.87L
(09 Mar 2026)Delivery %+7.3% vs avg
57.3%
(09 Mar 2026)Avg Volume (20D)20-day average
0.69L
(09 Feb - 09 Mar)Avg Delivery %Trend ↑
50.0%
(09 Feb - 09 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Sanofi India Ltd
2.91 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Alivus Life Sciences Ltd |
 Alembic Pharmaceuticals Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Caplin Point Laboratories Ltd
Caplin Point Laboratories Limited (CPL) is a prominent Indian pharmaceutical company specializing in the development, manufacturing, marketing, and export of generic and branded pharmaceutical formulations. Established in 1990 and headquartered in Chennai, India, CPL has built a significant presence in the Indian pharmaceutical market and beyond through its diverse product portfolio and extensive distribution network.
The company's product range is exceptionally broad, encompassing a wide array of dosage forms to cater to various therapeutic needs. This includes solid oral formulations like tablets and capsules, various injectable options such as injections, powder for injections, and pre-filled syringes, and a variety of topical preparations such as ointments, creams, gels, and sprays. CPL also manufactures liquid orals, softgel capsules, ophthalmic products, suppositories, ovules, pre-mix bag formulations, inhalers, dry syrups, lyophilized vials, emulsion injections, and IV infusions. This extensive portfolio allows CPL to address a large spectrum of medical conditions and patient demographics.
CPL's business model focuses on both generic and branded pharmaceutical products. While the production and distribution of generic medications form a substantial part of their operations, enabling them to offer cost-effective alternatives to branded drugs, they also actively develop and market their own branded products, allowing them to participate in both value and volume-based segments of the market. This dual approach provides a degree of stability and diversification, mitigating risks associated with relying solely on one market segment.
The company’s success is driven by its integrated approach, encompassing all stages of the pharmaceutical value chain, from research and development to manufacturing and distribution. This vertical integration provides greater control over quality, cost, and time-to-market, contributing to CPL's competitiveness in a highly competitive global pharmaceutical landscape. Their commitment to exports further enhances their market reach and revenue streams. In short, CPL is a fully integrated pharmaceutical company focused on delivering a diverse range of quality medications to both domestic and international markets.
COMPANY FACTS - CAPLIPOINT
Registered Address
3rd Floor, Ashvich Towers, No 3,, Developed Plots Industrial Estate, Perungudi
Chennai
TAMIL NADU
IN
Tel: 914428156653
Website:https://www.caplinpoint.net/
Investor Relations:http://www.caplinpoint.net/investor.aspx
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 3,406
IPO Date: 16/11/1994
MANAGEMENT - CAPLIPOINT
Mr. Chingelput Paarthipan
Non-Executive Chairman of the Board
Mr. D. Muralidharan
Chief Financial Officer
Mr. G. Venkatram
Compliance Officer, General Counsel, Company Secretary
Dr. Sridhar Ganesan
Managing Director, Executive Director
Mr. S. Deenadhayalan
Non-Executive Independent Director
Dr. Chanderkanta Gariyali
Non-Executive Independent Director
Dr. R. Nagendran
Non-Executive Independent Director
Mr. Ranganathan Vijayaraghavan
Non-Executive Independent Director
Investor Questions Answered
Caplin Point Laboratories Ltd (CAPLIPOINT) Stock FAQs
Get answers to the most common questions about Caplin Point Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Caplin Point Laboratories Ltd (CAPLIPOINT) is ₹1,684.1. Today, the stock has gained by ₹13.50 (0.81%), trading in a range of ₹1,665.6 to ₹1,690. The stock opened at ₹1,689.9 with a trading volume of 43,345 shares.
Caplin Point Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹13,093.4 crores, P/E ratio of 21.34, ROE of 9.88%, and ROCE of 25.80%. The dividend yield stands at 0.49%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Caplin Point Laboratories Ltd (CAPLIPOINT) is ₹2,395, while the 52-week low is ₹1,599. Currently trading at ₹1,684.1, the stock is 10.7% away from its 52-week low and 29.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Caplin Point Laboratories Ltd stock at ₹1,684.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 21.34 and P/B ratio of N/A. Today's performance shows a gain of 0.81%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Caplin Point Laboratories Ltd offers a dividend yield of 0.49%, which means for every ₹100 invested at the current price of ₹1,684.1, you can expect to receive approximately ₹0.49 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Caplin Point Laboratories Ltd's key financial metrics include: P/E Ratio: 21.34, P/B Ratio: N/A, ROE: 9.88%, ROCE: 25.80%, Dividend Yield: 0.49%, EPS: ₹80.49, Book Value: ₹375.01, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹13,093.4 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Caplin Point Laboratories Ltd stock opened at ₹1,689.9 and is currently trading at ₹1,684.1, showing a gain of ₹13.50 (0.81%). The intraday high is ₹1,690 and low is ₹1,665.6. The trading volume stands at 43,345 shares, indicating moderate market participation today.
Caplin Point Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 21.34, which means investors are willing to pay ₹21.34 for every ₹1 of earnings. With an EPS of ₹80.49, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Caplin Point Laboratories Ltd has a market capitalization of ₹13,093.4 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,684.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Caplin Point Laboratories Ltd has a book value of ₹375.01 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,684.1, which is 349.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Caplin Point Laboratories Ltd has a Return on Equity (ROE) of 9.88% and Return on Capital Employed (ROCE) of 25.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Caplin Point Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Caplin Point Laboratories Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Caplin Point Laboratories Ltd has an Earnings Per Share (EPS) of ₹80.49, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,684.1 and P/E ratio of 21.34, investors are paying 21.34 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Caplin Point Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Caplin Point Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Caplin Point Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (21.34), ROE (9.88%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹1599.00 - ₹2395.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1684.10) with book value (₹375.01) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Caplin Point Laboratories Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,684.1 is 84105x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Caplin Point Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1599.00 - ₹2395.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 43,345 shares. 5) Valuation Risk - P/E of 21.34 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Caplin Point Laboratories Ltd operates in the industry with key metrics: P/E ratio of 21.34, ROE of 9.88%, market cap of ₹13,093.4 crores, and dividend yield of 0.49%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Caplin Point Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,684.1, with a 52-week range of ₹1599.00 to ₹2395.00. Based on fundamentals like P/E (21.34), ROE (9.88%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Caplin Point Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1684.10. 2) Fundamental Deterioration - Declining ROE (currently 9.88%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Caplin Point Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.49%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu